CLBT
Cellebrite DI Ltd.
CLBT trails on the overall score without a compensating advantage in the available component scores.
NVDA
NVIDIA Corporation
NVDA has the edge over CLBT overall, supported by stronger valuation and stronger modeled upside.
CLBT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Strong | |
| Strong |
CLBT's revenue, cash flow and balance sheet are currently healthy, and its profitability is stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
CLBT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.1x | $1.64 | -85% |
| Forward | 33x | $10.89 | — |
| Fair | 44x | $10.10 | -7.3% |
| Current | 47x | $10.89 | — |
| Expensive | 62x | $14.35 | +32% |
Historical ranges are pointers, not guarantees.
CLBT's PE is in its fair range at 47x, but its recent earnings include one-off gains. If earnings grow as analysts expect, today's price would be 33x next year's earnings.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over CLBT in the historical PE scenario, which offers more potential upside but is not a forecast.
CLBT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for CLBT, but weaker profitability.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
CLBT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.33 | +46% |
| Q2 2026 | $0.23 | +$0.99 |
| Q1 2026 | $0.29 | +$1.25 |
| Q4 2025 | $0.31 | +$1.70 |
| Q3 2025 | $0.31 | +$1.86 |
| Q2 2025 | -$0.76 | -$0.24 |
| Q1 2025 | -$0.96 | -$0.39 |
| Q4 2024 | -$1.39 | -$0.96 |
| Q3 2024 | -$1.55 | -$1.23 |
CLBT has returned to profit: it earned $0.23 per share over the past year, after losing money the year before. Its recent earnings include one-off gains.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over CLBT on earnings, with more consistent year-over-year improvement.
CLBT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $131.1M | +16% |
| Q1 2026 | $128.3M | +19% |
| Q4 2025 | $128.8M | +18% |
| Q3 2025 | $126M | +18% |
| Q2 2025 | $113.3M | +18% |
| Q1 2025 | $107.5M | +20% |
| Q4 2024 | $109M | +17% |
| Q3 2024 | $106.9M | +27% |
CLBT's revenue has grown year over year every quarter since early 2021: $131M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 5.8% | -6.9 points |
| Q1 2026 | 7.1% | -4.3 points |
| Q4 2025 | 16% | +1.7 points |
| Q3 2025 | 15% | -3.1 points |
| Q2 2025 | 13% | -0.3 points |
| Q1 2025 | 11% | +1.1 points |
| Q4 2024 | 14% | -1.7 points |
| Q3 2024 | 18% | +2.2 points |
CLBT's operating margin was 5.8% last quarter, down 6.9 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over CLBT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over CLBT on profitability, with a higher operating margin.
CLBT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $14.5M | -50% |
| Q1 2026 | $16.8M | -9.1% |
| Q4 2025 | $78.3M | +27% |
| Q3 2025 | $30M | -25% |
| Q2 2025 | $29M | +138% |
| Q1 2025 | $18.5M | +134% |
| Q4 2024 | $61.7M | +59% |
| Q3 2024 | $39.8M | +42% |
CLBT generated $140M in free cash flow over the past year, down 6.3% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over CLBT on cash flow, with more consistent year-over-year improvement.
CLBT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +711K shares |
| 1 year | +1.5% | +3.8M shares |
| 3 years | +34% | +64.7M shares |
| 5 years | +35% | +65.6M shares |
| Available history | +35% | +65.6M shares |
CLBT has 253M diluted shares, up 1.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $11,000 |
CLBT hasn't bought back shares in the past year.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over CLBT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
CLBT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | -0.9x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2023 | -0.8x | Net Cash |
| Q2 2023 | -0.6x | Net Cash |
| Q1 2023 | -0.4x | Net Cash |
| Q4 2022 | -0.3x | Net Cash |
| Q3 2022 | -0.4x | Net Cash |
CLBT has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CLBT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.7 | Neutral |
| Stochastic | 32.9 | Neutral |
CLBT's weekly RSI is 42 (neutral) and its Stochastic is 33 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
CLBT PE vs Technology Sector
| Metric | CLBT | Sector median | Relative |
|---|---|---|---|
| PE | 47x | 28x | 67% above |
| PE % | 55 | 39 | 16 pts above |
CLBT is trading at 47x earnings, a 67% premium to the Technology sector's median of 28x, though its recent earnings include one-off gains.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over CLBT on valuation relative to its sector.
CLBT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.5 | 5.1% below |
| 20 week MA | $12.6 | 14% below |
| 50 week MA | $13.9 | 22% below |
| 100 week MA | $16.1 | 32% below |
| 200 week MA | $13.1 | 17% below |
CLBT is in a downtrend: it's below all five of its weekly moving averages, and 17% below its 200-week average.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has the edge over CLBT on trend strength, trading above more of its moving averages.
CLBT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.66 | $10.5 | +8.8% |
| 2021 | $10.5 | $8.10 | -23% |
| 2022 | $8.10 | $4.18 | -48% |
| 2023 | $4.18 | $8.66 | +107% |
| 2024 | $8.66 | $22.2 | +156% |
| 2025 | $22.2 | $18.4 | -17% |
| 2026 YTD | $18.4 | $10.9 | -41% |
CLBT's yearly returns have swung widely, from +156% in 2024 to −48% in 2022. It's down 41% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over CLBT on returns for 2026, with the stronger performance.